1. Home
  2. Topics
  3. Pharmaceutical Executive Magazine Features RaQualia: December Issue Cover Story Highlights the Company’s Venture Model

Topics

 

Pharmaceutical Executive Magazine Features RaQualia:
December Issue Cover Story Highlights the Company’s Venture Model

RaQualia Pharma Inc. (RaQualia) announced today that Pharmaceutical Executive Magazine featured the company in the cover story of its December 2011 issue. The article is entitled, “RaQualia’s New Spin on the Startup” and was written by the magazine’s Editor-in-Chief William Looney. The piece discusses RaQualia’s genesis as a new venture and its collaboration-centric model. Looney focuses on what makes the company unique and the implications for both Japan and the industry:

 

RaQualia is not just another small-cap enterprise struggling to build a product portfolio with other peoples' funds. The additive element is the pressure its very presence places on the conventional wisdom that Japan lacks an entrepreneurial culture, where new ideas fail because the only choice is between the "salary man" culture of bureaucratic malaise or the "samurai code" of winner take all. RaQualia is carving out a third way focused on teamwork, trust, and partnered collaboration to achieve a level of R&D productivity that exceeds what has been possible in Japanese life sciences to date…the RaQualia model poses a subtle challenge to its industry peers—and to Japanese industrial policy writ large. The question is whether Japan's best days as a pace-setter in medicines innovation are behind it. Or is RaQualia a breakthrough precedent that must be allowed to succeed?

 

Excerpt from “RaQualia’s New Spin on the Startup,” Pharmaceutical Executive, December 2011

 

Upon the article’s release, RaQualia President and CEO Dr. Atsushi Nagahisa commented, “we are honored and delighted to be featured in Pharmaceutical Executive magazine, a thought leader in our industry. This piece is a very nice way to end the year. 2011 has been a year of tremendous productivity for RaQualia and our pipeline, and we look forward to next year with great anticipation.”

 

For more details on the article, please see:

 

http://pharmexec.findpharma.com/pharmexec/Leadership+Column/RaQualias-New-Spin-on-the-Startup/ArticleStandard/Article/detail/752341?contextCategoryId=48158

 
####

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Facilities
Access
Press Release
Research & Development
Collaboration
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Anidulafungin
Ziprasidone
Dalbavancin
EP4 Antagonist
Cyclooxygenase-2 (COX-2) Inhibitor
Ghrelin Receptor Agonist
5-HT4 Partial Agonist
Acid Pump Antagonist
5-HT2B Antagonist
CB2 Agonist
Motilin Receptor Agonist
Licensing
Shareholder and Investor Information
To our Shareholders and Investors
Vision, Management Principle and Culture
Corporate Governance
Stock Quotes
Outline of Securities Matters
IR Library
IR Calendar
Disclaimer
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Corporate Introduction Video
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release
Topics